4//SEC Filing
MCNEIL ROBERT G 4
Accession 0001140361-09-001641
CIK 0000883697other
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 6:42 PM ET
Size
17.2 KB
Accession
0001140361-09-001641
Insider Transaction Report
Form 4
MCNEIL ROBERT G
Director10% Owner
Transactions
- Conversion
Common Stock
2009-01-16$3.00/sh+413,766$1,241,298→ 3,005,255 total(indirect: See footnote.) - Purchase
Common Stock
2009-01-16$3.50/sh+1,142,857$4,000,000→ 2,591,489 total(indirect: See footnote.) - Purchase
Warrants
2009-01-16+171,432→ 171,432 total(indirect: See footnote.)Exercise: $1.20From: 2009-01-16Exp: 2014-01-16→ Common Stock (171,432 underlying) - Conversion
Convertible Notes
2009-01-16$999999.90/sh→ 0 total(indirect: See footnote.)Exercise: $3.00From: 2008-07-24Exp: 2009-07-24→ Common Stock (346,446 underlying) - Conversion
Convertible Notes
2009-01-16$200000.00/sh→ 0 total(indirect: See footnote.)Exercise: $3.00From: 2008-12-04Exp: 2009-07-24→ Common Stock (67,320 underlying)
Holdings
- 11,986
Common Stock
Footnotes (6)
- [F1]Represents the number of shares issued upon conversion of the convertible notes at $3.00 per share and such conversion amount included the principal amount and any accrued and unpaid interest on the notes. Some convertible notes were originally convertible at $0.15 per share, but the conversion price increased to $3.00 per share after the 1 for 20 reverse split of the Company's common stock on November 29, 2008.
- [F2]Represents the principal amount of the convertible notes purchased and does not include any accrued and unpaid interest on the notes.
- [F3]Represents the number of shares of common stock into which the notes are convertible and such conversion amount includes the principal amount and any accrued and unpaid interest on the notes.
- [F4]Such conversion price was increased from $0.15 to $3.00 per share following the 1 for 20 reverse split of the Company's common stock on November 29, 2008.
- [F5]The warrants were issued pursuant to a Subscription Agreement, dated January 16, 2009, by and between ReGen Biologics, Inc. (the "Company") and each of the investors named therein. Each investor acquired common stock of the Company at $3.50 per share and without additional consideration, the Company provided 15% warrant coverage to each investor exercisable for additional shares of common stock.
- [F6]The securities are held by Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling Ventures Management VI, Sanderling VI Beteiligungs GMBH & Co KG, Sanderling VI Limited Partnership, Sanderling Venture Partners V Co-Investment Fund, L.P., Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Beteiligungs GMBH & Co KG, Sanderling V Limited Partnership, Sanderling Ventures Management V, Sanderling IV Biomedical Co-Investment Fund, L.P., Sanderling Venture Partners II L.P., Sanderling Venture Partners IV Co-Investment Fund, L.P. and/or Sanderling Ventures Limited L.P. Dr. McNeil is an affiliate of each of the foregoing entities.
Documents
Issuer
REGEN BIOLOGICS INC
CIK 0000883697
Entity typeother
Related Parties
1- filerCIK 0001216992
Filing Metadata
- Form type
- 4
- Filed
- Jan 20, 7:00 PM ET
- Accepted
- Jan 21, 6:42 PM ET
- Size
- 17.2 KB